Category Archives: Business and Investments

Latest From Business and Investments

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

David Thomas

With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market. Is it a bubble? David Thomas, director of Industry Research and Analysis at BIO took up these questions during the opening plenary lunch of the 12th Annual BIO Investor Forum. What’s his short answer? Not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Successful Public-Private Partnerships

According to BayBio, biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors. Gail Maderis, ‎President & CEO at BayBio, debuted their preliminary whitepaper entitled “Successful Public-Private Partnerships” today at the 2013 BIO Investor Forum. BayBio surveyed nearly 100 biotech and foundation CEOs, vice presidents of research, directors of patient advocacy and others across the United States. Following Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Kicks Off Amid Industry Optimism

San Francisco skyline

Today, the BIO Investor Forum kicks off in San Francisco, Calif. BioWorld’s Catherine Shaffer paints a positive picture of the industry (subscription required) highlighting the strong IPO activity and heightened interest in the sector among investors. The conference reflects the upward momentum of the industry with increased expected attendance among both companies and investors. The JOBS Act is widely viewed as the underlying reason for these positive trends in the industry as the law helped Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Investor Forum Interview with Regado Biosciences

regado-115x76

BIO is very excited to be hosting the BIO Investor Forum next week in San Francisco. The BIO One-on-One Partnering System has already scheduled over 640 meetings, which is a 50% increase over last year. Investor and company registration is also trending higher, including the number of presenting companies. The One-on-One Compass has been profiling these companies slated to present at the conference, and recently spoke to the CEO of Regado Biosciences, David Mazzo. Please Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

JOBS Act Deconstructed: Regulatory Relief

Capitol

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act marks a key departure from the previous one-size-fits-all regulatory approach for companies conducting a public offering.  Emerging growth companies (EGCs) are now subject Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,